# Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Source: https://onco.cc/trials/nct07486089/  
OnCo record `nct07486089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine in her2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) is a phase 1/2 interventional study registered as NCT07486089 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care. Conditions listed: Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07486089
- Phase: 1/2
- Setting: Phase 1/2, Biomarker-guided, Open-label Study of Allogeneic Dual-target CAR-NK Cells Directed Against HER2/ERBB2, MUC1, and/or ROR1 in Patients With Advanced or Metastatic Breast Cancer (Including HER2-positive and Triple-negative Disease).
- Sponsor: Beijing Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07486089: https://clinicaltrials.gov/study/NCT07486089

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07486089.json